Skip to main content

Table 10 The VRC01 susceptibility of AE-Env clones containing G185, N185 or E185, and the derived mutants

From: Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site

 

IC50of VRC01 (μg/ml)a

 

Mutation(s)b

Env clone

Wild-type

N186Q

N197Q

N186Q/N197Q

E185D/N186Q

G185D/N197Q

N185D/N197Q

E185D/N197Q

G185D/N186Q/N197Q

N185D/N186Q/N197Q

E185D/N186Q/N197Q

21PL2

>2c

 

0.17

   

0.03

    

47CC11

>2

 

>2

  

>2

     

50PB2

0.07

 

0.03

   

0.01

    

52PB3

>2

 

0.16

    

0.03

   

52PL4

>2

 

0.25

    

0.08

   

52PL7

>2

  

>2

      

>2

60PB2

0.28

 

0.08

   

0.04

    

60PL2

>2

 

0.02

   

0.02

    

62PL1

>2

  

>2

    

>2

  

65CC4

1.20

0.28

  

0.32

      

98CC2

0.38

 

0.19

  

0.21

     

101PL1

0.50

  

0.04

     

0.12

 

102CC2

>2

 

0.35

    

0.06

   

104PB4

>2

 

>2

   

>2

    
  1. aIC50 of VRC01 for suppressing viral replication was calculated using GraphPad Prism 5 software. Data are shown as the means of at least two independent experiments.
  2. bSingle or multiple amino acid mutations were introduced into AE-Env-recombinant viruses. Amino acid numbering is based on HXB2 Env gp120.
  3. cIC50 is >2 μg/ml.
Back to article page

Retrovirology

ISSN: 1742-4690

Contact us